| First Author | Tarade D | Year | 2018 |
| Journal | Oncogene | Volume | 37 |
| Issue | 2 | Pages | 139-147 |
| PubMed ID | 28925400 | Mgi Jnum | J:254259 |
| Mgi Id | MGI:6110374 | Doi | 10.1038/onc.2017.338 |
| Citation | Tarade D, et al. (2018) The HIF and other quandaries in VHL disease. Oncogene 37(2):139-147 |
| abstractText | Mutations in VHL underlie von Hippel-Lindau (VHL) disease, a hereditary cancer syndrome with several subtypes depending on the risk of developing certain combination of classic features, such as clear cell renal cell carcinoma (ccRCC), hemangioblastoma and pheochromocytoma. Although numerous potential substrates and functions of pVHL have been described over the past decade, the best-defined role of pVHL has remained as the negative regulator of the heterodimeric hypoxia-inducible factor (HIF) transcription factor via the oxygen-dependent ubiquitin-mediated degradation of HIF-alpha subunit. Despite the seminal discoveries that led to the molecular elucidation of the mammalian oxygen-sensing VHL-HIF axis, which have provided several rational therapies, the mechanisms underlying the complex genotype-phenotype correlation in VHL disease are unclear. This review will discuss and highlight the studies that have provided interesting insights as well as uncertainties to the underlying mechanisms governing VHL disease. |
